Suzhou, China
Atom Therapeutics, established in 2012, is a China-based clinical stage biotechnology company with a mission to develop orally delivered small molecule drugs for inflammatory and metabolic diseases. Its focus on conditions like chronic gout, which currently lack effective treatments, sets it apart in the Biotechnology and Health Care industries.
The company’s leading drug candidate, ABP-671, is designed to treat chronic gout. It boasts higher potency and reduced toxicity compared to existing options and is scheduled for global Phase 3 trials in 2022. Additionally, ABP-6016 has shown promise in preclinical trials for treating NASH, potentially addressing a growing cause of liver diseases.
Most recently, Atom Therapeutics secured a CNY600.00M Series D investment on 16 October 2023. The round was led by prominent investors including Kaitai Capital, NNFE Fund Management, Fortune Capital, Unifortune, and HuaJin Securities, reflecting strong confidence in the company's innovative pipeline.
